A comparison of two commercially available Escherichia coli J5 vaccines against E. coli intramammary challenge.

The efficacy of two commercially available Escherichia coli J5 bacterins was investigated. Jersey cows were randomly assigned to one of three treatment groups: 1) unvaccinated controls, 2) vaccinated with J.VAC (Merial Limited, Athens, GA), and 3) vaccinated with J5 bacterin. All cows were vaccinated at drying off and at 2 wk before anticipated calving. Cows that were vaccinated with the J5 bacterin also received a third immunization at calving. One quarter of each cow was challenged with approximately 64 cfu of E. coli at 14 to 30 d postcalving. Immunization by either vaccine did not influence the severity of coliform mastitis; however, the mean number of colony-forming units of E. coli recovered from challenged quarters was significantly lower for immunized cows than for control cows at 144 h postchallenge. Serum and mammary secretion immunoglobulin (Ig)G, IgG1, and IgG2 titers against E. coli J5 whole-cell antigens were enhanced in vaccinated cows. Serum and mammary secretion IgM were not different among treatment groups. Somatic cell counts in milk from challenged quarters, rectal temperatures, and the clinical status of cows following intramammary challenge were not different among treatment groups.

Effect of supplemental chromium on antibody responses of newly arrived feeder calves to vaccines and ovalbumin.

Two trials were conducted to investigate the effects of supplemental chromium (Cr) from organic sources (Cr chelate and high Cr yeast) on antibody responses of newly arrived feeder calves following vaccination with infectious bovine rhinotracheitis (IBR), para-influenza-3 (PI3), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD) and Pasteurella haemolytica and ovalbumin (OVA). Using cross bred steer calves purchased at sales in Ontario, vaccines and OVA were given on d 0 and 21 after arrival in the feedlot. Immune responses of calves were measured as serum specific antibody titres against all antigens on d 0 and 28 or d 35. The anti-OVA antibody responses (trial 2) were further investigated by measuring antibody concentrations of calves weekly until d 55 after arrival in the feedlot. Supplemental Cr (0.14 ppm) from an amino acid-chelated source had no effect on antibody responses to IBR, P13 and BRSV, but enhanced (P < 0.05) antibody titres of calves in response to the BVD vaccine on d 28 or d 35. Supplemental Cr from Cr yeast had no effect on antibody titres of calves to any vaccines. Chromium from both sources (trial 1 and 2) had no effect on antibody responses of calves following vaccination with P. haemolytica. However, supplemental Cr (0.75 ppm) from Cr yeast enhanced (P < 0.05) serum antibody responses of calves to OVA during the primary response (d 14) and secondary response (d 35) following immunization. These data confirmed our previous finding that supplemental Cr can enhance humoral immune response of market-transit stressed calves, but its enhancement on vaccine efficacy was antigen-dependent and variable.

Comparison of protection of experimentally challenged cattle vaccinated once or twice with a Pasteurella haemolytica bacterial extract vaccine.

Three groups of calves (15-18 per group) were injected twice at a 3-week interval with 2 doses of phosphate buffered saline (PBS, CONTROL group), 2 doses of PRESPONSE, a Pasteurella haemolytica A1 bacterial extract vaccine (PRESPONSE-2 group) or 1 dose of PBS followed by a 2nd vaccination with 1 dose of PRESPONSE (PRESPONSE-1 group). Three weeks after the 2nd vaccination, the calves were challenged intratracheally with P. haemolytica A1. Calves were evaluated clinically for 3 days prior to challenge and for 5 days after challenge. Six days postchallenge, calves were either euthanized or sent to slaughter and the lungs were evaluated for percent pneumonic tissue. There was a significant effect of single or double application of vaccine on clinical scores (P = 0.0409). Percent pneumonic tissue at necropsy was significantly affected by vaccine group (P = 0.014). Calves in the CONTROL group had significantly higher percent pneumonic tissue after arcsine transformation (45.30%) than calves in any group receiving PRESPONSE, regardless of vaccination frequency (25.18% and 25.78%, for calves receiving 2 doses or 1 dose of PRESPONSE, respectively). Both serum toxin neutralizing and direct agglutinating titers were negatively correlated with percent pneumonic tissue. Most importantly, 1 dose of PRESPONSE was as efficient as 2 doses at eliciting a protective immune response. It is concluded that the presence of P. haemolytica as a natural commensal in the upper respiratory tract of the calf can effectively prime the animal, and allow the animal to respond in an anamnestic nature to only 1 dose of this vaccine.

Efficacy of a feed-additive antibacterial combination for improving feedlot cattle performance and health.

The effectiveness of a feed-additive antimicrobial combination for improving feedlot performance and health was tested using 4325 high-risk feeder calves randomly allocated to a control group or an experimental group. The experimental group received the conventional ration plus a feed additive containing 700 mg per head/day of chlortetracycline and sulfamethazine from arrival at the feedlot to day 56 of the feeding period. The inclusion of the feed additive to the ration significantly improved average daily gain for days 0-28 (P = 0.0163) and 0-56 (P = 0.0001), and the feed conversion for days 0-28 (P = 0.0061) and 0-56 (P = 0.0004). Additionally, the use of the feed additive significantly reduced the rate of bovine respiratory disease morbidity for days 0-28 (P = 0.0014) and 0-56 (P = 0.0001), the rate of relapses and mortality for days 0-56 (P = 0.0151 and P = 0.0209, respectively), and the rate of animals diagnosed with chronic respiratory disease for days 0-28 and 0-56 (P = 0.0009 and P = 0.0002, respectively). Performance and health improvements produced by the use of the feed additive were cost-effective.

Effects of recombinant bovine somatotropin on nutritional status of dairy cows during pregnancy and of their calves.

Objectives of this trial were to evaluate effects of rbST on the nutritional status of 24 Holstein cows during pregnancy and of their calves from birth to weaning. All cows conceived during injection with either a placebo or 350 mg of rbST in a sustained-release vehicle every 14 d commencing 98 to 112 d postpartum for their entire lactation. In Experiment 1, blood samples were collected at 90, 180, and 270 d postconception in cows. Concentrations of urea, glucose, albumin, total proteins, Ca, P, insulin, cortisol, hemoglobin, and hematocrit were unaffected by treatment as well as BW, body condition scores, and energy balances at conception and during pregnancy. Days open and calving interval were not significantly different but were numerically increased by 31 d in rbST-injected cows. Nonesterified fatty acids, bST, and insulin-like growth factor-I in plasma were elevated significantly in rbST-injected cows. In Experiment 2, blood samples were collected at birth and at 1, 3, 5, and 7 wk in calves born from cows of Experiment 1. Circulating concentrations of glucose, nonesterified fatty acids, albumin, total proteins, hemoglobin, insulin, cortisol, bST, insulin-like growth factor-I, and hematocrit, blood pH, blood gases and buffer capacity, birth weight and rate of weight gain, height at withers, and heart girth from birth to weaning were not different due to treatment of dam. However, some parameters were significantly different based on age and sex. These data support previous assumptions that the magnitude of the modifications in nutrient partitioning produced by rbST do not affect the hierarchy of the partitioning process for the calf.

Effects of recombinant bovine somatotropin on nutritional status and liver function of lactating dairy cows.

Twenty-four high producing, multiparous Holstein cows were utilized to evaluate effects of long-term administration of sustained-release rbST on blood pH, gases, buffer capacity, circulating metabolites and hormones, and on liver lipid content and functions during lactation. Treatment, commencing 98 to 112 d postpartum and continued until d 305, consisted of a subcutaneous injection of a placebo or 350 mg of rbST every 14 d. Milk and 3.5% FCM were increased significantly by rbST, but milk fat and protein content, feed intake, energy balance, corrected feed efficiency for milk production, and body condition scores were unaffected. Somatotropin decreased blood pH and buffer capacity by decreasing bicarbonate without affecting blood partial pressures of oxygen or carbon dioxide. Concentration of plasma albumin was decreased and nonesterified fatty acids, glucose, insulin, rbST and insulin-like growth factor-I were increased by treatment. Total plasma proteins and cortisol, hemoglobin, and hematocrit were unaffected. Liver DM, total lipid and triacylglycerol contents, and plasma 3-hydroxybutyrate and glutamic oxalacetic transaminase were not affected by rbST, but the percentage of triacylglycerol in total lipids was increased. Results of this experiment suggest that rbST exhibited lipolytic and diabetogenic activities in lactating dairy cows in vivo and that these effects might be important for the increase in nutrient partitioning toward the mammary gland elicited by rbST.